Literature DB >> 7232045

Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus.

R B Cole, S Abman, K U Aziz, S Bharati, M Lev.   

Abstract

An infant with Ebstein's malformation of the tricuspid valve and severe pulmonic stenosis underwent a 39-day course of prostaglandin E1 infusion, and a histologic study of the ductus arteriosus was undertaken after autopsy. There were marked alterations in the ductal and juxtaductal structures following this prolonged infusion of prostaglandin E1. The internal elastic lamella of the ductus was disrupted in many areas. The media showed widespread areas of disruption with cavity formation. The adventitia adjacent to the junction of the ductus with the pulmonary artery was thickened and infiltrated with mononuclear cells. The nerve trunks in the adventitia were markedly infiltrated with mononuclear cells and showed cavitation as well as considerable surrounding edema. Mucopolysaccharides were increased throughout the ductus. These changes produced increased fragility of the ductal and juxtaductal structures, thus increasing the likelihood of spontaneous aneurysms and rupture, or of tearing or rupture at the aortic and pulmonary junctions at the time of surgical closure of the ductus. Unusual fragility of the ductus, pulmonary artery, and aorta has been observed during ligation of the ductus following prostaglandin E infusions lasting seven and ten days. Additionally, another patient who had received prostaglandin E infusion for six days demonstrated aneurysmal fullness to the ductus arteriosus at autopsy. The histologic findings and intraoperative experience in this study suggest that there may be a real danger of spontaneous or surgically related rupture of the ductus arteriosus after prolonged infusion of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7232045

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

Review 1.  PROSTAGLANDINS IN CONGENITAL HEART DISEASE.

Authors:  M Sharma; M Sasikumar; S D Karloopia; B N Shahi
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Pharmacologic manipulation of the ductus arteriosus in the neonate: a physiologic basis and current state of the art.

Authors:  S K Sanyal; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

3.  New drugs, more complications--old drugs, new complications: drug-related sequelae of neonatal intensive care.

Authors:  E G Kassner
Journal:  Bull N Y Acad Med       Date:  1984-06

4.  Pathology of the ductus arteriosus treated with prostaglandins: comparisons with untreated cases.

Authors:  A L Calder; J A Kirker; J M Neutze; M B Starling
Journal:  Pediatr Cardiol       Date:  1984 Apr-Jun       Impact factor: 1.655

Review 5.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

6.  Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.

Authors:  E D Silove; D G Roberts; J V de Giovanni
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

7.  Hypoplastic left heart syndrome: report of an operation utilizing the ductus arteriosis in outflow reconstruction.

Authors:  J M Levett
Journal:  Tex Heart Inst J       Date:  1986-12

8.  Aneurysmal change of the ductus arteriosus after prostaglandin E1 administration for pulmonary atresia: demonstration with magnetic resonance imaging.

Authors:  S Tsubata; I Hashimoto; F Ichida; A Miyazaki; T Okada; A Murakami; H Morita; K Fukahara
Journal:  Pediatr Cardiol       Date:  1994 Jan-Feb       Impact factor: 1.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.